44
2023-06-25 12:00:01
The biotechnology equipment manufacturer took investors by surprise by issuing a warning on its 2023 results on the evening of June 16. It now expects a drop in turnover of 2% to 5%, once morest an increase of 2% to 4% previously. Its expected EBITDA margin, at the very high level of 35% posted in 2021 and 2022 (when the company was boosted by the production of vaccines once morest Covid), is reduced to 30%, a profitability close to 2019.
REDUCTION DES STOCKS
1687697346
#Heavy #warning #results
